What options may exist if GLP-1 coverage through Medicaid ends during treatment?

If Medicaid GLP-1 coverage ends, options include appeals, manufacturer programs, or discussing physician-supervised compounded medications with a provider.

Why Medicaid Coverage for GLP-1s Can Change

Medicaid is a joint federal and state program, meaning coverage rules for GLP-1 drugs like Ozempic, Wegovy, or Mounjaro can vary significantly by state and change over time. What is covered in one state may require special authorization or not be covered at all in another.

States periodically update their Preferred Drug Lists (PDLs) or change the clinical criteria for coverage. This can lead to new requirements like step therapy (trying less expensive medications first) or stricter rules around BMI and related health conditions.

A change in your personal eligibility for Medicaid, often due to an increase in income, can also result in a loss of coverage for all prescriptions, including GLP-1 agonists. This is a common reason for an abrupt stop in coverage.

Sometimes, a coverage denial is due to an administrative error or a failure to renew a prior authorization (PA). Your physician's office can work with the Medicaid plan to identify the precise reason for the denial and determine the next steps.

The Appeals Process for a Coverage Denial

As a patient, you have a legal right to appeal a decision by your Medicaid plan to deny or discontinue coverage for a prescribed medication. The first step is to carefully review the written denial notice sent by the plan.

The denial notice will explain the reason for the decision and provide specific instructions and deadlines for filing an appeal. It is critical to act quickly, as these deadlines are strict.

Work directly with your healthcare provider to gather the necessary supporting documentation. A letter of medical necessity from your physician is one of the most important documents, detailing why continuous GLP-1 treatment is essential for managing your condition.

Your state's Medicaid office or the managed care organization (MCO) that administers your plan will have a formal process for submitting the appeal, which can typically be done online, by mail, or via fax.

Manufacturer Patient Assistance Programs (PAPs)

Major pharmaceutical companies, including Novo Nordisk (maker of Wegovy and Ozempic) and Eli Lilly (maker of Zepbound and Mounjaro), operate Patient Assistance Programs (PAPs) that can provide medication at no cost to qualifying individuals.

These programs have strict eligibility requirements, primarily based on household income relative to the Federal Poverty Level. Applicants are typically required to submit proof of income and other financial documentation.

A significant hurdle is that most PAPs explicitly exclude patients who are enrolled in any government-funded insurance program, including Medicaid. This is often the case even if Medicaid is not covering the specific GLP-1 drug.

Despite these restrictions, it is always worth checking the current terms and conditions for programs like NovoCare and the Lilly Cares Foundation, as eligibility criteria can be updated. Your provider's office may also have information on these programs.

Continuity with Physician-Supervised Compounded Medications

When brand-name, FDA-approved GLP-1s are not accessible due to coverage or cost issues, some patients work with their providers to consider compounded medications for their [weight loss](/weight-loss) treatment plan.

Compounded medications are prepared in licensed U.S. pharmacies based on a physician's specific prescription. They can be formulated to contain the same active pharmaceutical ingredient found in brand-name drugs, such as semaglutide or tirzepatide.

It is crucial to understand that compounded medications are NOT FDA-approved. They have not undergone the same extensive clinical trials to evaluate their safety, efficacy, and manufacturing quality as brand-name drugs.

For this reason, compounded GLP-1s should only be considered under the close supervision of a physician. Your provider must source the medication from a reputable, state-licensed compounding pharmacy to ensure proper oversight and quality control.

Bottom Line

An unexpected loss of Medicaid coverage for a GLP-1 medication can be disruptive, but several potential pathways exist to maintain treatment continuity and protect your health.

First, work with your doctor to understand the reason for the denial and to initiate a formal appeal. This is often the most direct route to restoring coverage for the FDA-approved medication.

While exploring manufacturer assistance, be prepared for the common restrictions placed on Medicaid recipients. For some, discussing physician-supervised compounded medications may be a viable alternative to stopping treatment altogether.

Ultimately, the most important step is to have an open conversation with your healthcare provider to weigh the risks and benefits of all available options for your specific medical situation. This article is for informational purposes only and does not constitute medical advice.

Drafted by the GOAL.MD Authority Engine and approved editorially by GOAL.MD staff. This page has not received its own physician review. Physician-supervised telehealth. More at goal.md/answers.